Synonym
UC-1010; UC 1010; UC1010; U-0949; U 0949; U0949; NSC97078; NSC97078; NSC 97078; NSC-97078; Isopregnanolone; Allopregnanolone; Sepranolone;
IUPAC/Chemical Name
1-((3S,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one
InChi Key
AURFZBICLPNKBZ-FZCSVUEKSA-N
InChi Code
InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16-,17+,18-,19-,20-,21+/m0/s1
SMILES Code
CC([C@H]1CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Sepranolone, a pregnane with hypnotic, and sedative properties, interferes with the development of rapid tolerance to the anxiolytic effect of ethanol.
In vitro activity:
Sepranolone has potential in glioblastoma treatment. allo suppresses GBM cell survival by decreasing DPYSL3/S100A11 expression and inducing DNA damage. Sepranolone enhanced temozolomide (TMZ)-suppressed cell survival and proliferation of TMZ-resistant cells. In particular, sepranolone enhanced TMZ-inhibited cell migration and TMZ-induced apoptosis. Sepranolone significantly decreased the levels of DPYSL3, S100A11, and S100A4, reflecting the poor prognosis of glioblastoma patients
Reference: J Steroid Biochem Mol Biol. 2022 May;219:106067. https://pubmed.ncbi.nlm.nih.gov/35114375/
In vivo activity:
Sepranolone has promise as a potential treatment for premenstrual dysphoric disorder (PMDD). In a group of women with pure PMDD, Sepranolone reduced Total DRSP scores by 75% compared with 47% following placebo. There were no severe adverse events reported during the treatment and safety parameters remained normal during the study.
Reference: Psychoneuroendocrinology. 2017 Jun;80:46-55. https://pubmed.ncbi.nlm.nih.gov/28319848/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
3.3 |
10.46 |
|
| Ethanol |
5.5 |
17.27 |
|
| Methanol |
1.0 |
3.14 |
|
| Acetonitrile |
1.0 |
3.14 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
318.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Feng YH, Lim SW, Lin HY, Wang SA, Hsu SP, Kao TJ, Ko CY, Hsu TI. Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. J Steroid Biochem Mol Biol. 2022 May;219:106067. doi: 10.1016/j.jsbmb.2022.106067. Epub 2022 Jan 31. PMID: 35114375.
2. Jolivel V, Brun S, Binamé F, Benyounes J, Taleb O, Bagnard D, De Sèze J, Patte-Mensah C, Mensah-Nyagan AG. Microglial Cell Morphology and Phagocytic Activity Are Critically Regulated by the Neurosteroid Allopregnanolone: A Possible Role in Neuroprotection. Cells. 2021 Mar 21;10(3):698. doi: 10.3390/cells10030698. PMID: 33801063; PMCID: PMC8004004.
3. Bäckström T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, Panay N, O'Brien S. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021 Nov;133:105426. doi: 10.1016/j.psyneuen.2021.105426. Epub 2021 Sep 23. PMID: 34597899.
4. Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017 Jun;80:46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1. PMID: 28319848.
In vitro protocol:
1. Feng YH, Lim SW, Lin HY, Wang SA, Hsu SP, Kao TJ, Ko CY, Hsu TI. Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. J Steroid Biochem Mol Biol. 2022 May;219:106067. doi: 10.1016/j.jsbmb.2022.106067. Epub 2022 Jan 31. PMID: 35114375.
2. Jolivel V, Brun S, Binamé F, Benyounes J, Taleb O, Bagnard D, De Sèze J, Patte-Mensah C, Mensah-Nyagan AG. Microglial Cell Morphology and Phagocytic Activity Are Critically Regulated by the Neurosteroid Allopregnanolone: A Possible Role in Neuroprotection. Cells. 2021 Mar 21;10(3):698. doi: 10.3390/cells10030698. PMID: 33801063; PMCID: PMC8004004.
In vivo protocol:
1. Bäckström T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, Panay N, O'Brien S. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021 Nov;133:105426. doi: 10.1016/j.psyneuen.2021.105426. Epub 2021 Sep 23. PMID: 34597899.
2. Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017 Jun;80:46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1. PMID: 28319848.
1: Singhal M, Modi N, Bansal L, Abraham J, Mehta I, Ravi A. The Emerging Role of Neurosteroids: Novel Drugs Brexanalone, Sepranolone, Zuranolone, and Ganaxolone in Mood and Neurological Disorders. Cureus. 2024 Jul 31;16(7):e65866. doi: 10.7759/cureus.65866. PMID: 39219949; PMCID: PMC11364262.
2: Cadeddu R, Van Zandt M, Santovito LS, Odeh K, Anderson CJ, Flanagan D, Nordkild P, Pinna G, Pittenger C, Bortolato M. Prefrontal allopregnanolone mediates the adverse effects of acute stress in a mouse model of tic pathophysiology. Neuropsychopharmacology. 2023 Aug;48(9):1288-1299. doi: 10.1038/s41386-023-01603-6. Epub 2023 May 17. PMID: 37198434; PMCID: PMC10354086.
3: Tiranini L, Nappi RE. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Fac Rev. 2022 Apr 28;11:11. doi: 10.12703/r/11-11. PMID: 35574174; PMCID: PMC9066446.
4: Bäckström T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, Panay N, O'Brien S. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021 Nov;133:105426. doi: 10.1016/j.psyneuen.2021.105426. Epub 2021 Sep 23. PMID: 34597899.
5: Bäckström T, Das R, Bixo M. Positive GABAA receptor modulating steroids and their antagonists: Implications for clinical treatments. J Neuroendocrinol. 2022 Feb;34(2):e13013. doi: 10.1111/jne.13013. Epub 2021 Aug 1. PMID: 34337790.
6: Murina PF, Graziottin A, Bagot O, Panay N, Thamkhantho M, Shaw SW. Real-World Practices and Attitudes Towards Intimate Self- Care: Results From An International Women's Survey. J Gynecol Obstet Hum Reprod. 2021 Dec;50(10):102192. doi: 10.1016/j.jogoh.2021.102192. Epub 2021 Jun 24. PMID: 34175471.
7: Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017 Jun;80:46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1. PMID: 28319848.
